Mitapivat
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Discovery of 8-quinolinesulfonamide phenylimidazole-based PKM2 agonists for the prevention and delay of aortic dissection.
Journal: European journal of medicinal chemistry
Published: September 24, 2025
The ENERGIZE trial: Is mitapivat ready to take center stage in NTDT management?
Journal: Med (New York, N.Y.)
Published: August 08, 2025
Efficacy and safety of Mitapivat in sickle cell disease: a systematic review.
Journal: Expert opinion on pharmacotherapy
Published: July 07, 2025
Efficacy and safety of Mitapivat in sickle cell disease: a systematic review.
Journal: Expert opinion on pharmacotherapy
Published: July 07, 2025
Potent Fluorescent Probe for Target-Engagement Studies of Allosteric Pyruvate Kinase Modulators.
Journal: Angewandte Chemie (International ed. in English)
Published: June 26, 2025
Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.
Journal: Blood reviews
Published: June 25, 2025
Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review.
Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review.
Journal: Expert review of hematology
Published: June 17, 2025
Fluorescent binding assay for allosteric ligands of liver pyruvate kinase.
Journal: European journal of medicinal chemistry
Published: May 09, 2025
Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare?
Journal: HemaSphere
Published: April 26, 2025
Mitapivat for non-transfusion-dependent thalassaemia.
Journal: Lancet (London, England)
Published: March 14, 2025
Mitapivat therapy in a patient with nonsense homozygous mutation of the Pyruvate Kinase L/R gene: a case report.
Journal: Blood transfusion = Trasfusione del sangue
Published: February 28, 2025
Last Updated: 02/24/2026